|
Announcing the Launch of New Accu-Chek® Active
Diabetes monitoring made easy
 This
month, an advanced version of the Accu-Chek Active blood glucose meter is being
introduced to the market - the popular choice of millions of satisfied customers.
The new device combines user-friendly handling with a number of premium features.
This will make it much easier for people with diabetes to make sure that their
doctor receives all the data needed for optimal treatment. Notably, the new
Accu-Chek Active system allows to flag blood glucose results before and after
meals. Postprandial values have moved into the spotlight recently due to their
importance in the context of cardio-vascular incidents. To enable the regular
monitoring of these data, the device is particularly easy to handle, comes up
with a modern, ergonomic design, and helps to ensure reliable data at every
measurement. Up to 350 values can be stored within the device and can be displayed
at the next doctor's appointment. Thus, Accu-Chek offers a new generation of
affordable meters facilitating comprehensive diabetes management based on exact
and reliable data.
Ergonomic design for higher acceptance and discrete use
Surveys have shown that more than half of all people with diabetes occasionally
skip measurements, either because they forget, can not afford the test strips,
or because they find it embarrassing to take a measurement in public1. The new
Accu-Chek Active system addresses this concern in a number of ways. Its ergonomic
design makes it so easy to use that people of all ages and levels of technological
proficiency will feel at ease using it. With its big, easy-to-read display and
only two conveniently spaced buttons, the device offers a nearly intuitive look-and-feel,
while the overall appearance allows discrete use in almost any situation.
Reliable results increase user confidence
Many people with diabetes do not trust their measurements entirely, nearly a
third is sometimes unsure whether the figures displayed are really accurate1.
Here, the new Accu-Chek Active system constitutes a huge step towards user confidence.
Its technology allows for reliable results at the first time. To ensure an accurate
reading, the device signals the user if there's not enough blood on the strip
or the strip has expired. Users can even compare the displayed test result with
the color code on the test strip itself to reassure a correct measurement, without
having to use a second strip.* And since accurate results translate into accurate
treatment, an improvement in confidence marks an important step towards optimal
diabetes management.
Detailed data to keep diabetes management on track
In fact, the Accu-Chek Active system now offers functions
to mark and evaluate the pre- and post-meal blood glucose values; the latter
have moved into the focus of attention as a major independent cardiovascular
risk factor over the past years. The new Accu-Chek Active system provides the
option to flag these values of particular importance and thus supports a precise
evaluation of the metabolic situation. Furthermore, the averages of pre- and
post-meal values for the last 7, 14 or 30 days can be retrieved from the meter's
memory and displayed directly on its screen. For a more comprehensive analysis
of the metabolic situation, the Accu-Chek Active meter is compatible with the
Accu-Chek information management solutions. The built-in infrared window supports
a wireless download of collected data to a computer via the Accu-Chek Smart
Pix device reader with no need for any software installation. The new Accu-Chek
Active system is also compatible with the test strips used with the predecessor
model, so a transition to the new device can be made as smoothly as possible.
Reference:
1 Koschinsky T, Lederle M, Rose-Fröhlich S. Blutzuckerselbstmanagement-Report
Deutschland 2006.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused
healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's
biggest biotech company and an innovator of products and services for the early
detection, prevention, diagnosis and treatment of diseases, the Group contributes
on a broad range of fronts to improving people's health and quality of life.
Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation,
and is a market leader in virology. It is also active in other major therapeutic
areas such as autoimmune diseases, inflammatory and metabolic disorders and
diseases of the central nervous system. In 2008, Roche had over 80,000 employees
worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted
sales of 45.6 billion Swiss francs. Roche Diabetes Care posted 2007 sales of
3.2 billion Swiss francs. Genentech, United States, is a wholly owned member
of the Roche Group. Roche has a majority stake in Chugai Pharmaceuticals, Japan.
For more information: www.roche.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring
systems and a global leader for diabetes management systems and services. For
more than 30 years, the Accu-Chek brand has been committed to enable people
with diabetes to live life as normal and active as possible as well as to help
healthcare professionals manage their patients' condition in an optimal way.
Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals
innovative products and services and comprehensive solutions for convenient,
efficient and effective diabetes management spanning from blood glucose monitoring
through information management to insulin delivery. The Accu-Chek brand encompasses
blood glucose meters, insulin delivery systems, lancing devices and data management
systems.
* Only the test results displayed by the meter should be used for therapeutic
decisions. The color comparison serves only as a plausibility check of the test
results.
For more information please contact:
Accu-Chek ExtraCare Helplines
30 300 400 or 1800 22 6020
or visit www.accu-chek.in
All trademarks used or mentioned in this release are legally protected.
|
